Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Shiraz University of Medical Sciences | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The present study aimed to evaluate the effect of a combination of insulin resistance reducing agents pre and post coronary artery bypass grafting surgery on post-operative blood glucose and oxidative stress regulation.
The present study aimed to evaluate the effect of a combination of insulin resistance reducing agents pre and post coronary artery bypass grafting surgery on post-operative blood glucose and oxidative stress regulation. The sample size was estimated to be 92 (23 in each group). The participants of the study were selected from the non-diabetic patients scheduled for CABG. The patients were allocated to four groups using balanced block randomization method:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Supplement pre CABG | Experimental | Consumption of the supplement 7 days before surgery and placebo 30 days post surgery |
|
| Supplement post CABG | Experimental | Consumption of placebo 7 days before surgery and supplement 30 days post surgery |
|
| Supplement pre and post CABG | Experimental | Consumption of the supplement 7 days before and 30 days post surgery |
|
| Placebo | Placebo Comparator | Consumption of placebo 7 days before and 30 days post surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Supplement pre CABG | Dietary Supplement | One sachet of the supplement was consumed daily for 7 days before surgery. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Serum glucose | It was measured in 5 steps: 1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation | 37days |
| serum insulin | It was measured in 5 steps: 1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation | 37 days |
| Hemoglobin A1C | It was measured in 4 steps: 1 week before the operation, Just before the operation, 1 week post operation, 30 days post operation | 37 days |
| Insulin Resistance | Calculated by HOMA calculation equation It was calculated in 5 steps: 1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation | 37 days |
| Measure | Description | Time Frame |
|---|---|---|
| Body Composition changes | It was measured in 4 steps: 1 week before the operation, Just before the operation, 1 week post operation, 30 days post operation | 37 days |
| malondialdehyde | It was measured in 5 steps: 1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohammad Hassan Eftekhari, professor | Shiraz University of Medical Sciences | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Supplement post CABG | Dietary Supplement | One sachet of the supplement was consumed daily for 30 days after surgery |
|
| Supplement pre and post CABG | Dietary Supplement | One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG |
|
| Placebo | Drug | One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG |
|
| 37 days |
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided